DVA vs SGRY vs RDNT Stock Comparison

Davita, Surgery Partners and RadNet Prices as of Oct 26, 2026 Peers: Industry group
DVA Davita Inc.
$184.14 +3.2% 1M +42.5% 1Y
Market cap
$11.74B
P/E
13.9x
Revenue (TTM)
$14.01B
Div. yield
–
Healthcare Services Healthcare
6 wins
RDNT RadNet, Inc.
$70.05 -1.0% 1M -16.0% 1Y
Market cap
$5.76B
P/E
–
Revenue (TTM)
$2.27B
Div. yield
–
Healthcare Services Healthcare
4 wins

Head to Head

10 decided of 12

Davita leads on 6 of the 12 questions below (Davita 6, RadNet 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDVASGRYRDNTLeader
Larger companyMarket capitalisation $11.74B $2.99B $5.76B DVA
Cheaper on earningsLower P/E, profitable companies only 13.9x -33.8x -272.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.0x 55.4x 132.2x DVA
Faster revenue growthRevenue growth, trailing twelve months +6.4% +4.0% +18.9% RDNT
More profitableNet margin, trailing twelve months 6.0% -2.6% -0.9% DVA
Better return on capitalReturn on invested capital 17.0% 5.3% 1.5% DVA
Less leveragedLower net debt / EBITDA 3.6x 6.3x 2.5x RDNT
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +42.5% +2.0% -16.0% DVA
Better 5-year returnAnnualised price return, 5 years +10.7%/yr -10.3%/yr +18.4%/yr RDNT
Less volatileAnnualised volatility, 1 year 45.3% 66.9% 42.1% RDNT
Higher overall scoreMean of the five percentile scores vs peers 68/100 55/100 39/100 DVA

Percentile Scorecard

DVASGRYRDNT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDVASGRYRDNT
Valuation 95 #6 of 93 84 #16 of 93 40 #56 of 93
Growth 35 #58 of 88 43 #51 of 88 22 #69 of 88
Profitability 84 #15 of 87 64 #32 of 87 45 #48 of 87
Financial Health 28 #72 of 100 31 #69 of 100 43 #57 of 100
Shareholder Returns 96 #3 of 56 – 42 #33 of 56
Overall 68 55 39
  • DVA ranked among 103 companies in Healthcare Providers
  • SGRY ranked among 103 companies in Healthcare Providers
  • RDNT ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDVASGRYRDNTSPY
1 month +3.2%+61.5%-1.0% -0.8%
3 months -22.1%+53.3%+13.9% +3.5%
6 months +22.7%+59.9%+21.3% +7.0%
Year to date +62.1%+50.5%-1.8% +12.2%
1 year +42.5%+2.0%-16.0% +13.0%
3 years +139.9%+3.7%+175.6% +86.3%
3 years, per year +33.9%+1.2%+40.2% +23.1%
5 years +66.0%-42.0%+132.8% +68.6%
5 years, per year +10.7%-10.3%+18.4% +11.0%
10 years +223.8%+26.6%+872.9% +258.0%
10 years, per year +12.5%+2.4%+25.6% +13.6%

Risk

MeasureDVASGRYRDNTSPY
Volatility, 1Y 45.3%66.9%42.1% 12.7%
Downside volatility, 1Y 41.1%65.5%42.4% 12.7%
Beta vs S&P 500, 1Y -0.030.821.02 1.00
Return / volatility, 1Y 0.940.03-0.38 1.02
Max drawdown, 5Y -47.0%-81.4%-56.2% -25.4%
From 52-week high -23.6%0.0%-17.1% -1.8%
52-week high $240.98$23.25$84.48 $779.14
52-week low $103.87$11.49$51.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDVASGRYRDNT
P/E now vs peer median 14.1xmedian 25.1x -33.8xmedian 25.1x -258.1xmedian 25.1x
P/S now vs peer median 0.8xmedian 1.6x 0.9xmedian 1.6x 2.4xmedian 1.6x
EV/EBITDA now vs peer median 7.7xmedian 14.5x 11.7xmedian 14.5x 25.1xmedian 14.5x
P/FCF now vs peer median 7.3xmedian 22.4x 16.2xmedian 22.4x -16.0xmedian 22.4x
P/B now vs peer median -15.4xmedian 3.1x 1.0xmedian 3.1x 4.0xmedian 3.1x
PEG now vs peer median 0.38median 0.66 1.96median 0.66 31.52median 0.66

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDVASGRYRDNT
Revenue $14.01B $3.37B $2.27B
Gross profit $4.53B – $261.62M
Operating income $2.13B $383.80M $70.78M
Net income $1.19B $48.10M $80.00K
Free cash flow $1.61B $187.60M -$344.77M
EPS (diluted) $12.82 $-0.69 $-0.27
Cash & equivalents $668.96M $216.70M $726.27M
Total debt $10.78B $3.75B $1.33B
Shares (diluted) 66.09M 128.83M 78.73M
Enterprise value $8.95B $2.15B $3.01B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDVASGRYRDNT
P/E 14.1x -33.8x -258.1x
P/FCF 7.3x 16.2x -16.0x
P/Operating cash flow 5.4x 11.8x 17.8x
P/S 0.8x 0.9x 2.4x
P/B -15.4x 1.0x 4.0x
P/Tangible book -11.8x 1.0x 4.8x
EV/EBITDA 7.7x 11.7x 25.1x
EV/EBIT 10.3x 17.1x 86.4x
EV/Revenue 1.6x 2.0x 2.7x
EV/FCF 13.6x 35.1x -17.7x
EV/Operating cash flow 10.0x 25.5x 19.7x
PEG (3Y EPS CAGR) 0.38 1.96 31.52

Growth

14 metrics
MetricDVASGRYRDNT
Revenue growth (1Y) 6.4% 4.0% 18.9%
Revenue CAGR (3Y) 6.1% 8.1% 14.1%
Gross profit growth (1Y) 5.8% – 17.8%
Gross profit CAGR (3Y) 9.5% – 11.7%
Operating income growth (1Y) 2.4% 6.1% 8.5%
Operating income CAGR (3Y) 18.3% 7.1% 5.9%
Net income growth (1Y) 3.2% 136.2% -99.3%
Net income CAGR (3Y) 18.9% 15.6% -74.7%
EPS growth (1Y) 18.6% 51.6% -35.8%
EPS CAGR (3Y) 36.8% -17.2% -8.2%
Operating cash flow growth (1Y) 17.8% -2.2% 18.5%
Operating cash flow CAGR (3Y) 3.7% 16.4% 19.6%
Free cash flow growth (1Y) 25.0% 7.0% -1,140%
Free cash flow CAGR (3Y) 5.9% 36.7% -66.2%

Profitability

14 metrics
MetricDVASGRYRDNT
Gross margin 32.4% – 11.5%
EBITDA margin 20.3% 16.7% 10.7%
Operating margin 15.2% 11.4% 3.1%
Pretax margin 10.5% 11.4% 1.5%
Net margin 6.0% -2.6% -0.9%
FCF margin 11.5% 5.6% -15.2%
Operating cash flow margin 15.7% 7.7% 13.7%
Return on equity – 2.6% 1.4%
Return on assets 6.8% 1.0% 0.5%
Return on invested capital 17.0% 5.3% 1.5%
Return on capital employed 14.4% 5.1% 2.1%
Asset turnover 0.8x 0.4x 0.6x
Cash conversion (OCF / net income) 1.8x 5.4x 3,876x
Stock comp / revenue 0.9% 0.3% 2.6%

Financial Health

11 metrics
MetricDVASGRYRDNT
Debt / assets 60.9% 46.6% 31.5%
Debt / equity -14.1x 1.2x 1.0x
Net debt / EBITDA 3.6x 6.3x 2.5x
Debt / FCF 6.7x 20.0x -3.9x
Liabilities / assets 104.3% 61.5% 67.0%
Equity / assets -4.3% 38.5% 33.0%
Interest coverage 3.6x – 1.0x
Current ratio 1.5x 1.9x 1.5x
Quick ratio 1.3x 1.4x 1.4x
Cash ratio 0.2x 0.4x 1.0x
Altman Z-score 1.67 0.88 1.81

Shareholder Returns

7 metrics
MetricDVASGRYRDNT
Dividend yield – – –
Net buyback yield 13.1% – -0.1%
Shareholder yield 13.1% – -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDVASGRYRDNT
Forward P/E 12.0xFY2026 55.4xFY2026 132.2xFY2026
EPS, next fiscal year $15.31FY2026 $0.42FY2026 $0.53FY2026
EPS growth, next FY +42.0%FY2026 -10.6%FY2026 +35.9%FY2026
EPS growth, the year after +13.8% -2.4% +71.7%
Revenue, next fiscal year $14.43BFY2026 $3.46BFY2026 $2.68BFY2026
Revenue growth, next FY +5.8%FY2026 +4.7%FY2026 +31.4%FY2026
Revenue growth, the year after -3.3% -1.2% -1.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDVASGRYRDNT
Held by institutions 91.0% 100.0% 100.0%
Institutions holding 622 189 328
Change in shares held, QoQ -5.0% -0.8% +6.0%
Institutions buying 303 111 175
Institutions selling 223 50 110
Buyers to sellers 1.36 2.22 1.59

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DVASGRYRDNT
DVA 1.00 0.10 0.02
SGRY 0.10 1.00 0.18
RDNT 0.02 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DVA, SGRY and RDNT?

Davita (DVA) is the largest by market capitalisation: Davita (DVA) $11.74B, Surgery Partners (SGRY) $2.99B, RadNet (RDNT) $5.76B.

Which company is growing faster?

RadNet (RDNT) grew revenue fastest over the trailing twelve months: Davita (DVA) +6.4%, Surgery Partners (SGRY) +4.0%, RadNet (RDNT) +18.9%.

Which company is more profitable?

Davita (DVA) has the highest net margin (Davita (DVA) 6.0%, Surgery Partners (SGRY) -2.6%, RadNet (RDNT) -0.9%). On return on invested capital, Davita (DVA) leads (Davita (DVA) 17.0%, Surgery Partners (SGRY) 5.3%, RadNet (RDNT) 1.5%).

Which stock has performed better?

Over the past year Davita (DVA) returned the most: Davita (DVA) +42.5%, Surgery Partners (SGRY) +2.0%, RadNet (RDNT) -16.0%. Over five years, RadNet (RDNT) compounded fastest (Davita (DVA) +10.7%/yr, Surgery Partners (SGRY) -10.3%/yr, RadNet (RDNT) +18.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, RadNet (RDNT) has been the steadiest (Davita (DVA) 45.3%, Surgery Partners (SGRY) 66.9%, RadNet (RDNT) 42.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DVA, SGRY and RDNT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Davita (DVA) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.